Industry Leaders Convene for Inaugural Global Medical Cannabis Summit
Creating an independent Medical Cannabis Hub to spearhead the future of medical cannabis to benefit all
The inaugural Global Medical Cannabis Summit (GMCS) recently concluded on Necker Island, convening an influential cross section of scientists, policy makers, industry leaders and advocates who committed to accelerating patient access to certified medical cannabis.
The Summit is a not-for-profit, annual event with the mission of ensuring that patients anywhere in the world have unimpeded access to safe medical cannabis.
The event welcomed a group of 40 industry leaders and experts from a broad range of backgrounds for the three-day event, including:
Dr Dedi Meiri, Lead Investigator at Technion Lab of Cancer Biology and Cannabinoid Research
Terry Booth, CEO of Aurora Cannabis
Ethan Nadelmann, Founder of the Drug Policy Alliance
Hon. Audley Shaw, Jamaican Minister of Industry, Commerce, Agriculture and Fisheries
José María Figueres, Former President of Costa Rica & President, Carbon War Room
Sir Richard Branson, Member of the Global Commission on Drug Policy
Kasia Malinowska-Sempruch, Director of the Open Society Global Drug Policy Program
Alexandra Chong, CEO of Jacana
Hon. Anne McLellan, Chair of the Cannabis Task Force for the Government of Canada
Carly Barton, Director of United Patients Alliance
The Summit comes at a time when the global cannabis industry is experiencing rapid growth that is fast surpassing outdated policy. Legalisation of medical cannabis is spreading globally – patient access, however, remains compromised by the inconsistent integration and slow implementation of policy around the world. In particular, legal regulation on an international scale has been slow to move forward in spite of the World Health Organization’s recommendation for cannabis and cannabis resin to be deleted from Schedule IV of the Single Convention on Narcotics Drugs in January 2019.
The Summit addressed the most critical issues facing the industry today, helping to accelerate and enhance patient access to medical cannabis. These include building consensus on key issues such as patient accessibility, education, research, and policy reform, as well as defining best practices for regulating medical cannabis on a global scale.
To tackle these critical issues, the GMCS introduced a collective pledge to create The Medical Cannabis Hub – an open-source collaborative, independent group. The Hub will ensure medical cannabis serves humanity in the best possible way, with a focus on industry stewardship and evidence-based data.
It will initially focus on three critical objectives:
Creating a shared hub for medical cannabis through standardised data and rapid learning
Building a network of 200+ scientists to help catalyse funding for research
Educating and sharing industry best practices to mobilize medical cannabis for the benefit of all
The Hub will be coordinated by an independent management team and further information on the Medical Cannabis Hub will be released in coming weeks.